Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)-Associated Lipodystrophy Syndrome and Stavudine-Triphosphate Intracellular Levels in Patients with Stavudine-Based Antiretroviral Regimens

被引:26
|
作者
Domingo, Pere [1 ]
Carmen Cabeza, Maria [1 ]
Pruvost, Alain [6 ]
Salazar, Juliana [3 ]
del Mar Gutierrez, Maria [1 ]
Mateo, Maria Gracia [1 ]
Domingo, Joan C. [4 ]
Fernandez, Irene [1 ]
Villarroya, Francesc [4 ]
Munoz, Jessica [1 ]
Vidal, Francesc [5 ]
Baiget, Montserrat [2 ]
机构
[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Infect Dis Unit, Barcelona 08025, Spain
[2] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Genet, Barcelona 08025, Spain
[3] Univ Barcelona, CIBERER U 705, Barcelona, Spain
[4] Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain
[5] Univ Rovira & Virgili, Hosp Univ Joan XXIII, Tarragona, Spain
[6] CEA, Inst Biol & Technol Saclay, SPI, Lab Etud Metab Medicaments, Gif Sur Yvette, France
关键词
REVERSE-TRANSCRIPTASE INHIBITORS; BLOOD MONONUCLEAR-CELLS; LAMIVUDINE-TRIPHOSPHATE; MITOCHONDRIAL TOXICITY; NUCLEOSIDE-ANALOG; ZIDOVUDINE PHOSPHORYLATION; HIV-1-INFECTED PATIENTS; CARBOVIR TRIPHOSPHATE; HIV; VIRUS;
D O I
10.1086/651117
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The link between human immunodeficiency virus/highly active antiretroviral therapy (HAART) associated lipodystrophy syndrome (HALS) and the use of thymidine analogues has been well established. However, to our knowledge, no relationship has been proven between intracellular levels of stavudine (d4T) and HALS. Methods. We measured peripheral blood mononuclear cell intracellular levels of d4T-triphosphate (TP) in patients who were receiving d4T as part of their antiretroviral regimens. d4T-TP levels were determined by a validated liquid chromatography-tandem mass spectrometry assay method. The diagnosis of HALS was made in accordance with the criteria of a lipodystrophy severity grading scale. The Student t test, Pearson correlations, 1-way analysis of variance with Bonferroni correction, and stepwise logistic regression were used for statistic analyses. Results. This was a cross-sectional study. There were 33 patients: 17 with HALS and 16 without HALS. The median concentration of d4T-TP for patients with HALS was 20.60 femtomoles (fmol)/1 x 10(6) cells (interquartile range [IQR], 14.90-26.92 fmol/1 x 10(6) cells) and for patients without HALS was 13.85 fmol/1 x 10(6) cells (IQR, 8.65-20.15 fmol/1 x 10(6) cells) (P = .013). The median d4T-TP intracellular level in patients who had developed an AIDS-defining condition was 22.50 fmol/1 x 10(6) cells ( IQR, 15.80-27.37 fmol/1 x 10(6) cells) and in those who had not was 14.40 fmol/1 x 10(6) cells (IQR, 10.80-20.40 fmol/1 x 10(6) cells) (P = .037). There were no statistically significant differences in d4T-TP intracellular levels with respect to the presence of metabolic syndrome, the clinical form of HALS (pure lipoatrophic vs mixed), the degree of facial lipoatrophy, the presence of hepatitis C virus infection, and the pair of nucleosides in HAART. d4T-TP levels correlated only with cumulative d4T exposure in time and dose. d4T-TP intracellular levels were independently associated with HALS (odds ratio, 1.58; 95% confidence interval, 1.08-2.32; P = .019). Conclusions. Intracellular levels of d4T-TP are strongly associated with the development of HALS.
引用
收藏
页码:1033 / 1040
页数:8
相关论文
共 50 条
  • [1] Evaluating the relationship between adherence to Highly Active Antiretroviral Therapy (HAART) and social and clinical characteristics in Chinese patients with HIV
    Wang, Yuan-Yuan
    Wang, Tang
    Yan, Hong
    D'Amato, Rik Carl
    Wang, Wei
    Li, Shi-Yue
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2019, 31 (01): : 14 - 18
  • [2] Metabolic Effects Associated to the Highly Active Antiretroviral Therapy (HAART) in AIDS Patients
    Domingos, Hamilton
    da Cunha, Rivaldo Venancio
    Miranda Paniago, Anamaria Mello
    Martins, Diego Mira
    Elkhoury, Eduardo Brandao
    de Souza, Albert Schiaveto
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2009, 13 (02): : 130 - 136
  • [3] Lipodystrophy syndrome associated with antiretroviral therapy in HIV patients: Considerations for psychosocial aspects
    Morais Fernandes, Ana Paula
    Sanches, Roberta Seron
    Mill, Judy
    Lucy, Daniel
    Palha, Pedro Fredemir
    Barcellos Dalri, Maria Celia
    REVISTA LATINO-AMERICANA DE ENFERMAGEM, 2007, 15 (05): : 1041 - 1045
  • [4] Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India
    Bhutia, Euden
    Hemal, Alok
    Yadav, Tribhuvan Pal
    Ramesh, K. L.
    AFRICAN HEALTH SCIENCES, 2014, 14 (02) : 408 - 413
  • [5] Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy
    Aurpibul, L.
    Puthanakit, T.
    Sirisanthana, T.
    Sirisanthana, V.
    HIV MEDICINE, 2008, 9 (05) : 317 - 321
  • [6] Pulmonary radiological characteristics in patients with HIV infection at the time of highly active antiretroviral therapy (HAART)
    Schlossbauer, T.
    Schmidt, G. P.
    Bogner, J. R.
    Sing, A.
    Reiser, M. E.
    Becker-Gaab, C.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (08) : 341 - 346
  • [7] Increased lipodystrophy is associated with increased exposure to highly active Antiretroviral therapy in HIV-infected children
    Viganò, A
    Mora, S
    Testolin, C
    Beccio, S
    Schneider, L
    Bricalli, D
    Vanzulli, A
    Manzoni, P
    Brambilla, P
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (05) : 482 - 489
  • [8] Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)
    Maschke, M
    Kastrup, O
    Esser, S
    Ross, B
    Hengge, U
    Hufnagel, A
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 69 (03): : 376 - 380
  • [9] HIV-associated bacteremia: How it has changed in the highly active antiretroviral therapy (HAART) era
    Tumbarello, M
    Tacconelli, E
    Donati, KD
    Citton, R
    Leone, F
    Spanu, T
    Cauda, R
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (02) : 145 - 151
  • [10] Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study
    Domingo, Pere
    del Mar Gutierrez, Maria
    Miguel Gallego-Escuredo, Jose
    Torres, Ferran
    Maria Mateo, Gracia
    Villarroya, Joan
    de los Santos, Ignacio
    Carles Domingo, Joan
    Villarroya, Francesc
    Del Rio, Luis
    Estrada, Vicente
    Giralt, Marta
    PLOS ONE, 2014, 9 (02):